• Molecular NameDorzolamide
  • SynonymNA
  • Weight324.446
  • Drugbank_IDDB00869
  • ACS_NO130693-82-2
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.33
  • pkaN/A
  • LogD (pH=7, predicted)-1.57
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.79
  • LogSw (predicted, AB/LogsW2.0)1.74
  • Sw (mg/ml) (predicted, ACD/Labs)2.95
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds3
  • TPSA151.33
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding33.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life4 months
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A